Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 1

Status

Unknown 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Observational 4Interventional 4

Sponsor

Cancer Type

Head & Neck 24Lymphoid 20Myeloid 4Other hematologic neoplasm 3Sarcoma 2Gastrointestinal 2Dermatologic 2Thoracic 1Gynecologic 1Genitourinary 1

Conditions

Myelodysplastic Syndromes 1349Leukemia, Myeloid, Acute 1133Leukemia, Myelogenous, Chronic, BCR-ABL Positive 713Leukemia 675Precursor Cell Lymphoblastic Leukemia-Lymphoma 646Myeloproliferative Disorders 527Leukemia, Myelomonocytic, Chronic 424Lymphoma, Non-Hodgkin 407Primary Myelofibrosis 384Multiple Myeloma 369Leukemia, Lymphocytic, Chronic, B-Cell 367Hodgkin Disease 348Leukemia, Myeloid, Chronic-Phase 304Lymphoma 291Blast Crisis 256Leukemia, Myeloid, Accelerated Phase 238Lymphoma, Mantle-Cell 231Lymphoma, Follicular 226Burkitt Lymphoma 224Polycythemia Vera 222Lymphoma, Large B-Cell, Diffuse 219Lymphoma, B-Cell, Marginal Zone 203Congenital Abnormalities 192Anemia, Refractory, with Excess of Blasts 187Lymphoma, Large-Cell, Immunoblastic 182Myelodysplastic-Myeloproliferative Diseases 175Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 173Thrombocythemia, Essential 167Neoplasms, Plasma Cell 161Hematologic Neoplasms 161

Interventions

pegaspargase 2Methylprednisolone 2Etoposide 2Doxorubicin 1Dexamethasone 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Epstein-Barr Virus Infections × Myeloid × Clear all
NCT01494103 2025-07-11

DOTTI

Baylor College of Medicine

Phase 1 Active not recruiting
15 enrolled
LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Epstein-Barr Virus Infections, Lymphohistiocytosis, Hemophagocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05775705 2023-03-20

L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH

Beijing Friendship Hospital

Phase 3 Not yet recruiting
25 enrolled
LymphoidMyeloid

Lymphoma, Epstein-Barr Virus Infections, Lymphohistiocytosis, Hemophagocytic

NCT02912702 2016-09-23

L-DEP as an Initial Treatment for EBV-HLH

Beijing Friendship Hospital

Phase 3 Unknown
120 enrolled
Myeloid

Epstein-Barr Virus Infections, Lymphohistiocytosis, Hemophagocytic

NCT02631109 2016-08-04

L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis

Beijing Friendship Hospital

Phase 3 Unknown
120 enrolled
Myeloid

Epstein-Barr Virus Infections, Lymphohistiocytosis, Hemophagocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡